{"entity":{"id":"paper-keynote-062-shitara-jama-oncol-2020","kind":"paper","name":"KEYNOTE-062: pembrolizumab or pembrolizumab plus chemotherapy versus chemotherapy in PD-L1-positive advanced gastric cancer","aka":[],"tldr":"In first-line PD-L1-positive gastric cancer, pembrolizumab alone was no worse than chemotherapy for survival but did not beat it, and adding it to chemotherapy did not help either; the exception was microsatellite-unstable tumours, which did dramatically better with pembrolizumab.","summary":"Phase 3 trial of 763 patients with untreated advanced gastric or junctional adenocarcinoma with PD-L1 combined positive score of 1 or more randomised to pembrolizumab, pembrolizumab plus chemotherapy, or chemotherapy.\n\nPembrolizumab was non-inferior to chemotherapy for overall survival (10.6 versus 11.1 months) and combination therapy was not superior; in the 50 patients with microsatellite instability-high tumours, median overall survival was not reached with pembrolizumab against 8.5 months with chemotherapy.","asOf":"2026-09-17","links":[{"label":"JAMA Oncol 2020","url":"https://doi.org/10.1001/jamaoncol.2020.3370"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/32880601/"}],"tags":[],"related":[],"cancers":["gastric-msi-high"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["keynote-062"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jama-oncology"],"dependsOn":[],"notes":[],"journal":"JAMA Oncology","year":2020,"doi":"10.1001/jamaoncol.2020.3370","pmid":"32880601","authors":"Shitara K, Van Cutsem E, Bang YJ, et al.","paperType":"rct","findings":["Pembrolizumab non-inferior to chemotherapy overall (10.6 vs 11.1 months).","Microsatellite instability-high: overall survival not reached vs 8.5 months with chemotherapy."],"whatItMeans":"Single-agent pembrolizumab is an option for microsatellite-unstable gastric cancer first line, whereas for the broader PD-L1-positive population chemo-immunotherapy from CheckMate 649 and KEYNOTE-859 became standard.","caveats":["Microsatellite-unstable subgroup was small and exploratory.","Early progression was more frequent with pembrolizumab alone."],"changedPractice":true,"participants":763},"route":"/key-papers/paper-keynote-062-shitara-jama-oncol-2020/","neighbours":{"cancer":[{"id":"gastric-msi-high","kind":"cancer","name":"Microsatellite-unstable (MSI-high) gastric cancer","route":"/cancers/gastric-msi-high/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"trial":[{"id":"keynote-062","kind":"trial","name":"KEYNOTE-062","route":"/trials/keynote-062/"}],"journal":[{"id":"jama-oncology","kind":"journal","name":"JAMA Oncology","route":"/journals/jama-oncology/"}]}}